FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Harbin Jixianglong Biotech Semaglutide Recall

Semaglutide, For Rx compounding use only, packaged in a) 1g

Harbin Jixianglong Biotech Co., Ltd. · Haerbin, N/A

Risk level
Class II
Reported by FDA
Mar 11, 2026
Recall ID
D-0379-2026
Check your lot numberHow we source this data

Summary

Harbin Jixianglong Biotech recalled Semaglutide starting Feb 13, 2026. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0379-2026 on Mar 11, 2026. Reason: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution. Status: Ongoing.

Why it was recalled

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Product description

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China

Lot numbers, UPCs & expiration codes

Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027

Where it was sold

Nationwide within the United States

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0379-2026
Classification
Class II
Status
Ongoing
Recall initiated
Feb 13, 2026
FDA report date
Mar 11, 2026
Quantity
N/A
Recall type
Voluntary: Firm initiated
Recalling firm
Harbin Jixianglong Biotech Co., Ltd.

Original FDA data

Every field from FDA enforcement report D-0379-2026, exactly as published.

Show all FDA fields
City
Haerbin
Status
Ongoing
Country
China
Event ID
98438
Address
North Of Baoan Road, East Of Changqing Street
Address (line 2)
Hulan District
Code information
Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027
Report date
Mar 11, 2026
Product type
Drugs
Recall number
D-0379-2026
Classification
Class II
Recalling firm
Harbin Jixianglong Biotech Co., Ltd.
Reason for recall
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
Voluntary / mandated
Voluntary: Firm initiated
Product description
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China
Distribution pattern
Nationwide within the United States
Recall initiation date
Feb 13, 2026
Initial firm notification
E-Mail
Center classification date
Mar 2, 2026

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0379-2026, published Mar 11, 2026. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls